Andre Turenne, Matchpoint Therapeutics CEO (Jen Randall Photography)

For­mer Voy­ager CEO An­dre Turenne makes a come­back with At­las-backed co­va­lent drug biotech 

Last May, An­dre Turenne re­signed from his CEO and pres­i­dent posts at Voy­ager to “pur­sue oth­er op­por­tu­ni­ties” af­ter the neu­ro­science biotech, once one half of ma­jor part­ner­ships with Sanofi, Ab­b­Vie and Neu­ro­crine, faced one set­back af­ter an­oth­er that put it and its gene ther­a­pies out of the clin­ic — though it’s now stag­ing a come­back with for­mer Bio­gen R&D chief Al San­drock at the helm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.